Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for...
$10 Million Acquisition Bolsters FITY's Leadership with Dr. Gennaro D'Urso as CEO and ChairmanMELBOURNE, Fla., March 20, 2025 (GLOBE NEWSWIRE)...
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of...
BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more...
Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications Proprietary sensing and...
JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
Conference call will be held today, Thursday, March 20 at 9:00 am ETCARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) --...
Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue...
The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of...
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high...
Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma ForumSOUTH SAN FRANCISCO, Calif., March...
Key findings support weekly induction of immune cell trafficking by Decoy20, a critical factor in effective cancer immunotherapyNEW YORK, March...
NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through...
MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the...
Transaction is part of the Company’s new corporate strategy to become a revenue generating biotechWARRINGTON, Pa., March 20, 2025 (GLOBE...
Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 StudyPHOENIX, March 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology...
REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March...
Visionary sector leaders Dan Menichella and Jo Brewer, PhD join as Non-Executive DirectorsBringing strengths in strategy, immuno-oncology science execution from bench to...
Olio Labs Identifies Why Women Experience Stronger Side Effects from GLP-1 DrugsThe Company's AI-Powered Combination Design Engine (CoDE) Maps Biological...